Table 1 The detailed information of MenSCs in the treatment of various diseases
Disease | Donor age | Experimental method | Effect | Reference |
|---|---|---|---|---|
DMD | N/A | Murine model, IM, 2 × 107 cells | Differentiation of myogenic cells after 3 W | Cui et al. [25] |
POF | N/A | Murine model, IP, 1 × 104 cells | Differentiation of ovarian granulosa cells after 21 D | Liu et al. [36] |
T1DM | N/A | Murine model, IV, 3 × 105 cells | Differentiation of β-cells after 14 D | Wu et al. [22] |
IUA | 24–38 | Murine model, Axillary subcutaneous, 1 × 106 cells | Differentiation of endometrial cells after 2 W | Zheng et al. [38] |
Sepsis | 24–38 | Murine model, IP, 2 × 106 cells | Immunomodulation of lower inflammatory responses after 40 H | Alcayaga-Miranda et al. [91] |
EC | 20–40 | Murine model, IV, 1 × 106 cells | Immunomodulation of regulation of B lymphocytes after 10 D | Xu et al. [47] |
EC | 20–30 | Murine model, IV, 1 × 106 cells | Immunomodulation of SDF-1/CXCR4 axis after 10 D | Li et al. [48] |
Transplant Vasculopathy | 30 | Murine model, Aorta, 1 × 106 cells | Immunomodulation of B7-H1 expression after 40 D | Ye et al. [92] |
GVHD | 18–45 | Murine model, IV, 1 × 106 cells | Immunomodulation of lower peripheral blood mononuclear cells after 14 D | Luz-Crawford et al. [45] |
IPF | 20–40 | Murine model, IV, 1 × 106 cells | Immunomodulation of immunosuppressive and antifibrosis effects after 2 W | Zhao et al. [49] |
Liver fibrosis | N/A | Murine model, IV, 5 × 105 cells | Paracrine effect of secreting MCP-1, IL-6, HGF, GRO, IL-8, and OPG after 2 W | Chen et al. [18] |
MI | N/A | Rat model, IM, 1.5 × 106 cells | Paracrine effect of activate AKT, ERK1/2 and STAT3 after 28 D | Jiang et al. [55] |
Stroke | N/A | Rat model, intracerebral, 0.75 × 106 cells | Paracrine effect of secreting VEGF, BDNF, and NT-3 after 14 D | Borlongan et al. [52] |
EOC | 40 | Murine model, SC, 2 × 106 cells | Paracrine effect of promote foxo3a after 28 D | Bu et al. [93] |
POF | 40 | Murine model, IV, 2 × 106 cells | Homing and migration of improving the renewal of germline stem cells after 2 W | Lai et al. [33] |
A549-induced tumor | 23–42 | Murine model, intratumoral, 1 × 106 cells | Homing and migration of target tumor sites after 5 D | Moreno et al. [83] |
POF | 25–30 | Murine model, IV, 2 × 106 cells | Homing and migration of improve the ovarian microenvironment after 21 D | Wang et al. [61] |
Cutaneous wound | N/A | Murine model, intradermal, 1 × 106 cells | Immunosuppressive/paracrine effects after 2 W | Cuenca et al. [44] |
OCD | 25–45 | Rabbit model, orthopotic, 7 × 105 cells | Differentiation/Regenerative capacity after 24 W | Khanmohammadi et al. [94] |
ALI | N/A | Murine model, IV, 1 × 106 cells | Reduce inflammation/paracrine effect After 72 H | Ren et al. [95] |
Spinal cord injury | N/A | Rat model, thoracic, 1 × 105 cells | Reduce inflammation/paracrine effect after 28 D | Wu et al. [53] |
MI | N/A | Rat model, IM, 1 × 106 cells | Secreting exosomal microrna-21 after 56 D | Wang et al. [72] |
Alzheimer’s disease | N/A | Murine model, hippocampus, 1 × 105 cells | Anti-inflammatory after 7 D | Zhao et al. [96] |
POI | 25–35 | Murine model, IV, 1 × 105 cells | Regulating the ECM-dependent FAK/AKT signaling after 40 D | Feng et al. [97] |
POF | N/A | Murine model, IV, 1 × 106 cells | Inhibiting GADD45b expression in the cell cycle after 28 D | Guo et al. [98] |
Cervical cancer | N/A | Murine model, subcutaneous, 5 × 106 cells | Mediate TGF-β1-mediated JNK/P21 signaling after 21 D | Liu et al. [99] |
HCC | N/A | Murine model, IV, 5 × 105 cells | DNA methylation after 36 D | Wu et al. [78] |
CLI | N/A | Rat model, IM, 1 × 106 cells | Secreting growth factors/inhibiting inflammatory responses after 14 D | Murphy et al. [54] |
Glioma | N/A | Rat model, Intratumoral, 3 × 106 cells | Inhibition of intracranial glioma growth after 14 D | Han et al. [100] |
Multiple sclerosis | 18–30 | Human model, intrathecal, 6 × 106 cells | Suppress immune responses after 12 M | Zhong et al. [88] |
Cardiac fibrosis | N/A | Rat model, IM, 2 × 106 cells | Inhibition of endothelial to mesenchymal transition after 7 D | Zhang et al. [101] |
AS | 20–40 | Human model, IM, 1 × 106 cells | Ensured embryo implantation after 24 M | Tan et al. [89] |
ALI | N/A | Murine model, IV, 1 × 106 cells | Downregulation of IL-1 and the upregulation of IL-10 after 48 H | Xiang et al. [59] |